Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of anti-Müllerian hormone after methotrexate vs laparoscopic treatment for tubal ectopic pregnancy
IRCT20240514061800N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of methotrexate in Ectopic pregnancy (EP) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Change in anti-Müllerian hormone (AMH) levels. Started Sep 2024; status: completed.
02
Drugs
methotrexate
03
Conditions
Ectopic pregnancy (EP)
Beyond the preview
Go deeper on IRCT20240514061800N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240514061800N4.